• letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Staff Reporter From: precisiononcologynews.com Janssen Pharmaceutical Companies, a unit of Johnson & Johnson, said on Tuesday that its investigational drug JNJ-61186372 (JNJ-6372) has been granted breakthrough therapy designation by the US Food and Drug Administration. The drug is being evaluated in non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed on or after ...
    The post Janssen Pharmaceutical Bispecific Antibody Granted Breakthrough Designation for Lung Cancer Treatment appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Conor Killmurray From: curetoday.com As CDK 4/6 inhibitors become a bigger part of the treatment of breast cancer, CURE® sat down with clinical nurse specialist Patricia Jakel to discuss the essentials about the drug. CDK 4/6 inhibitors have changed the way treatment is thought about and given for patients with breast cancer, but the cost and side effects associated ...
    The post Here’s What Patients With Breast Cancer Need to Know About CDK 4/6 Inhibitors appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Staff Reporter By: precisiononcologynews.com A new study published in Science Translational Medicine this week found that MET inhibitors in combination with BET inhibitors could be potent against high MYCN-expressing triple negative breast cancer. The authors of the study hope that their findings will accelerate development of BET inhibitors for TNBC, where there is an unmet need. TNBC accounts for ...
    The post Study Says Combination of MEK, BET Inhibitors May be Effective in Portion of Breast Cancer Patients appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Danielle Ternyila From: targetedonc.com Circulating free DNA (cfDNA) in the blood may be a more effective way to measure disease in patients with breast cancer and track the progression of the disease, according to a study from researchers at the Fox Chase Cancer Center.1 Liquid biopsies yield unique benefits compared with other genetic testing methods, such as collecting samples ...
    The post Liquid Biopsy Study Confirms Concordance With Tissue Biopsy in Breast Cancer appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Staff Reporter From: precisiononcologynews.com Researchers have homed in on BRCA1/2 mutations as a potential biomarker predictive of which early-stage breast cancer patients will respond to a neoadjuvant chemotherapy regimen containing epirubicin, paclitaxel, cyclophosphamide (iddEPC). Esther Pohl-Rescigno from University Hospital Cologne in Germany led the study published in JAMA Oncology last week. The secondary analysis was based on the 961-patient ...
    The post BRCA1/2-Positive Breast Cancer Patients May Respond to Certain Chemotherapy Regimens, Study Finds appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Diana Ernst, RPh From: empr.com Herzuma (trastuzumab-pkrb; Teva and Celltrion Healthcare), a biosimilar to Herceptin (trastuzumab; Genentech), is now available in the US for the same indications as the reference product. Specifically, Herzuma is indicated for: Adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with 1 high risk feature breast cancer as part of ...
    The post Biosimilar Herzuma Now Available for Breast, Gastric Cancer Treatment appeared first on Let Life Happen.